BTG loses out on sterling benefit due to hedging and dollar costs
14th Jul 2016 09:07
(ShareCast News) - Healthcare company BTG said it would make little gains from the collapse of the pound as its currency hedging contracts would negate the potential revenue benefits from the stronger dollar. The FTSE 250 company, in a statement issued ahead of its annual shareholder meeting and aft
Read moreWednesday broker round-up
8th Jun 2016 13:18
(ShareCast News) - Hochschild Mining: UBS downgrades to neutral with a target price of 160p. Esure Group: JP Morgan keeps at overweight with a 330p target. Royal Dutch Shell: RBC reiterates outperform with a target price of 2000p and JP Morgan stays atneutral with a target price of 1630p. National
Read moreRevenue jump boosts BTG full-year profits
17th May 2016 07:56
(ShareCast News) - Healthcare company BTG more than doubled full year pre-tax profits to £57.5m on the back of a 22% jump in revenues to £447.5m. The company said expected revenue for fiscal 2017 to be in the range of £485m-£515m, with selling general and administrative costs to be £160m-£170m and r
Read moreBTG buys Galil Medical for inital £58.3
6th May 2016 09:23
(ShareCast News) - Specialist healthcare company BTG said it was buying Galil Medical, a leading provider of cryoablation products for the treatment and palliative care of kidney and other cancers, for an initial £58.3m. BTG said it would also pay up to £17.6m in future regulatory and commercial mil
Read moreBTG exudes confidence ahead of final reuslts
5th Apr 2016 07:41
(ShareCast News) - Specialist healthcare company BTG was confident ahead of its final results on Tuesday, claiming reported group revenue for the year to 31 March was expected to be at the upper end of its guidance range of £410m-£440m, boosted by currency tailwinds. The growth at the FTSE 250 compa
Read moreFTSE 250 movers: Broker notes spur on big movers
15th Dec 2015 15:24
(ShareCast News) - The FTSE 250 looks to finish the day in the green, with the second-tier market up 228.85 point (1.36%) to 17,001.42 mid-afternoon Tuesday. Circassia Pharmaceuticals rose to the top of the ranks after RBC Capital Markets initiated coverage at 'top pick' for the company. "With intr
Read moreBTG rallies as RBC hails long-term growth prospects
15th Dec 2015 13:58
(ShareCast News) - RBC Capital Markets initiated coverage of specialist pharmaceutical company BTG at 'outperform' with a price target of 820p, saying it should be a long-term holding. It said the shares have underperformed materially over the past year and, while medium-term market expectations are
Read moreBTG wins US approval for BC Bead Lumi
14th Dec 2015 08:14
(ShareCast News) - Specialist pharmaceutical firm BTG said it had won US regulatory approval for its LC Bead Lumi radiation treatment. The company added that a trial of its PneumRx endobronchial coil implant for severe emphysema had produced positive results with all primary and secondary endpoints
Read moreBTG's interim profit soars thanks to solid growth across the board
10th Nov 2015 08:03
(ShareCast News) - Healthcare group BTG has posted an increase in interim pre-tax profit, boosted by solid growth across all of its divisions. In the six months to 30 September, the FTSE 250 group posted a 40.6% year-on-year increase in pre-tax profit to £52.9m, while revenue rose 20% to £229.6m. T
Read moreFTSE 250 movers: Just Retirement boosted by CMA merger clearance
28th Oct 2015 13:50
(ShareCast News) - After an initial stumble, the FTSE 250 fought its way back into positive territory over the day, By 1420 GMT, the UK mid-cap index was up 0.28% at just over 17,000 points, but not rising as fast as its blue chip sister index 0.85% gain. Pharmaceutical group BTG was given a shot i
Read moreFTSE 250 movers: Miners and energy stocks rally; Wizz Air crashes
7th Oct 2015 13:46
(ShareCast News) - London's FTSE 250 index was down 0.2% at 17,101.89 just after 1400 BST, underperforming the broader market. Miners were firmly on the front foot as metals prices advanced and the sector got a boost from an upbeat note by Morgan Stanley. The bank upgraded its stance on the European
Read moreFTSE 250 movers: Greggs surges on strong update; Acacia tumbles as output disappoints
6th Oct 2015 13:40
(ShareCast News) - London's FTSE 250 index was flat at 17,111.00 at 1400 BST, as investors took a breather following healthy gains in the previous session. Greggs surged after the bakery chain served up a tasty trading update. It said sales in the 13 weeks to October were slightly ahead of its expec
Read moreBTG full-year revenue to be in lower half of guidance
6th Oct 2015 07:59
(ShareCast News) - Pharmaceutical group BTG expects its full year revenue to be in the lower half of its guidance range, as interest in one of its treatment was yet to translate into sales growth. The FTSE 250 group said it expects revenue in the 12 months to the end of March 2016 to be between £410
Read moreInvestec affirms 'buy' rating for BTG, confident about varicose vein treatment
29th Jun 2015 14:51
Investec reiterated a 'buy' rating and price target of 647p for pharmaceuticals firm BTG after reappraising its key product Varithena. The bank said investors overreacted to concerns over BTG's earning profile, in particular the varicose vein treatment Varithena. "After interviewing physicians and
Read moreWednesday broker round-up
27th May 2015 07:57
Beazley: JP Morgan upgrades to overweight from neutral and sets 308p target, up from 255p. Hiscox: JP Morgan upgrades to overweight from neutral and ups target to 950p from 801p. Lancashire Holdings: JP Morgan improves target price to 642p from 589p, stays at neutral. Dixons Carphone: Exane keeps
Read more